Resultado da Busca
Há 7 horas · GSK is also considering using Arexvy in other patient groups to expand the shot in the future. The company is expected to report trial data later in 2024 in two separate groups of patients: people ages 18 to 59 who are at higher risk of severe RSV infection, and adults with compromised immune systems.
Há 7 horas · La Food and Drug Administration des États-Unis a approuvé vendredi l'utilisation élargie du vaccin contre le virus respiratoire syncytial de GSK chez les adultes âgés de 50 à 59 ans, ce qui ...
Há 7 horas · GSK plc announced that it has acquired Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics, for up to $50 million (approximately £39 million). Oligonucleotides have a unique ability to modulate gene expression, making them an attractive modality to ...
Há 7 horas · 智通财经APP获悉，葛兰素史克公司(GSK.US)在呼吸道合胞病毒(RSV)疫苗领域取得重大进展，其Arexvy疫苗获得美国食品药品监督管理局(FDA)批准，用于50至59 ...
Há 7 horas · About Press Copyright Contact us Creators Advertise Developers Terms Privacy Policy & Safety How YouTube works Test new features NFL Sunday Ticket Press Copyright ...
Há 9 horas · 미국 식품의약국은 금요일에 50세에서 59세 사이의 성인에게 GSK의 LSE:GSK 호흡기 세포융합 바이러스 (RSV) 백신의 확대 사용을 승인하여 해당 연령대에 대해 승인된 첫 번째 백신이 되었습니다. 아렉스비라는 이름의 이 백신과 경쟁사인 화이자 NYSE:PFE 및 모더나 NASDAQ:MRNA의 백신은 이미 60세 이상에 대해 ...
Há 7 horas · 智通财经APP获悉，葛兰素史克公司(GSK.US)在呼吸道合胞病毒(RSV)疫苗领域取得重大进展，其Arexvy疫苗获得美国食品药品监督管理局(FDA)批准，用于50至59岁感染风险较高的成年人群体。
